Skip to content

Investors
Join Us

<img width="224" height="61" src="https://femasys.com/wp-content/uploads/2021/11/Femasys-Logo.svg" class="custom-logo astra-logo-svg" alt="Femasys Logo" decoding="async" />

About Us
Our Focus
Our Pipeline
Resources
Contact Us

About Us
Our Focus
Our Pipeline
Resources
Contact Us
Investors
Join Us

<img width="224" height="61" src="https://femasys.com/wp-content/uploads/2021/11/Femasys-Logo.svg" class="custom-logo astra-logo-svg" alt="Femasys Logo" decoding="async" />

About Us
Our Focus
Our Pipeline
Resources
Contact Us
Investors
Join Us

BioWorld

Femasys Targets Male Infertility with Updated Trial Design

Media / By lsc-webmaster

With Roe overturned, Femasys’ permanent contraception has increased appeal

Media / By lsc-webmaster

Search

Recent Posts

US biomedical company launches intrauterine device for tubal evaluation
Femasys Selected by BioSpace as a 2023 Best Places to Work
Femasys Targets Male Infertility with Updated Trial Design
Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement
Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

Recent Comments

No comments to show.

Archives

January 2023
November 2022
October 2022
September 2022
August 2022
July 2022
June 2022
May 2022
February 2022
January 2022
December 2021
October 2021
July 2021
June 2021
May 2021

Categories

Board of Directors
Leadership
Media
Video

Privacy & Terms
Patents
Accessibility

Copyright © 2023 Femasys Inc.

FemaSeed, FemBloc, FemCerv, and FemVue are registered trademarks of Femasys Inc. FemCath and FemEMB are trademarks of Femasys Inc.